The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Patients with AAO-HNS Vertigo Control Class A or B
Timeframe: 1 month after treatment initiation
Percentage of Patients with AAO-HNS Vertigo Control Class A or B
Timeframe: 3 months after treatment initiation
Percentage of Patients with AAO-HNS Vertigo Control Class A or B
Timeframe: 6 months after treatment initiation
Difference in Dizziness Between Treatment Arms
Timeframe: 3 months after treatment initiation
Percentage of Subjects Experiencing Significant Hearing Fluctuation
Timeframe: 3 months after treatment initiation